Abstract 2043P
Background
Elderly patients are a heterogeneous group, ranging from fit to frail, with varying disease burden, comorbidities and ability to tolerate cancer-directed treatment. Defining treatment strategies in octogenarians with colorectal cancer (CRC) is challenging due to the high risk of complications and the likelihood of death from other causes. The aim of this study was to evaluate whether CCI and CFS can predict survival in octogenarians with CRC.
Methods
Patients aged 80 and over with CRC, seen at the Multidisciplinary tumor board at our center between January 2020 and December 2022 were evaluated in this study. CCI and CFS were calculated in all patients. Kaplan-Meier method was used to estimate the probability of 1-, 3- and 5-year survival rates (OS) regardless of treatment, and to compare OS estimates based on subjects’ characteristics, CCI and CFS scores.
Results
We analysed 149 patients, median age 82 (range 80-91), with 53% of patients with stage IV CRC. Death was confirmed in 65 patients (44%) during follow-up. Following CFS scoring, patients were classified as frail (44%), pre-frail (45%) and robust (9%). The univariate 1-, 3- and 5-year survival rate estimates in frail group were 89%, 56% and 29%, and in robust/pre-frail group 92%, 85% and 64%. Median OS estimate in frail group was 13.24 months (5.35-21.13), and in robust/pre-frail 113.02 months (56.41-169.63), which was statistically significant, p<0.01. According to CCI scale patients were divided in groups that scored 1-5 (13%), 6-7 (28%), 8-10 (31%) and more than 10 points (24%). In these CCI groups, median OS estimates were as follows: 59.5, NR, 40.4 and 8.28 months, respectively, which proved to be statistically significant (p<0.019). A binomial logistic regression was performed to ascertain the effects of ECOG performance status (PS), CFS and CCI on the likelihood that participants will survive 12 months. Of these three predictor variables, only PS was statistically significant in predicting 1-year survival in this model.
Conclusions
Geriatric assessments (CFS and CCI) were efficient in predicting survival in octogenarians with CRC, with potential implications for shaping the decision-making process for different treatment modalities.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06
2045P - Patient Reported Outcome Measures (PROMs) capturing therapy adherence of cancer patients: A systematic literature review
Presenter: Luise Richter
Session: Poster session 06